1. Home
  2. DBI vs CABA Comparison

DBI vs CABA Comparison

Compare DBI & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Designer Brands Inc.

DBI

Designer Brands Inc.

HOLD

Current Price

$6.96

Market Cap

375.2M

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$3.24

Market Cap

319.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DBI
CABA
Founded
1991
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
375.2M
319.6M
IPO Year
2005
2019

Fundamental Metrics

Financial Performance
Metric
DBI
CABA
Price
$6.96
$3.24
Analyst Decision
Hold
Strong Buy
Analyst Count
2
7
Target Price
$7.25
$14.57
AVG Volume (30 Days)
679.8K
2.9M
Earning Date
03-10-2026
01-01-0001
Dividend Yield
2.78%
N/A
EPS Growth
N/A
N/A
EPS
0.23
N/A
Revenue
$3,009,262,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.87
N/A
P/E Ratio
$31.33
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.18
$0.99
52 Week High
$8.75
$3.78

Technical Indicators

Market Signals
Indicator
DBI
CABA
Relative Strength Index (RSI) 47.04 60.30
Support Level $6.25 $2.11
Resistance Level $7.59 $3.34
Average True Range (ATR) 0.43 0.29
MACD -0.01 0.03
Stochastic Oscillator 42.02 59.77

Price Performance

Historical Comparison
DBI
CABA

About DBI Designer Brands Inc.

Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: